Clinical Aspects of Type 3 Long-QT Syndrome: An International Multicenter Study
BACKGROUND:Risk stratification in patients with type 3 long-QT syndrome (LQT3) by clinical and genetic characteristics and effectiveness of β-blocker therapy has not been studied previously in a large LQT3 population. METHODS:The study population included 406 LQT3 patients with 51 sodium channel mut...
Saved in:
Published in | Circulation (New York, N.Y.) Vol. 134; no. 12; pp. 872 - 882 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
by the American College of Cardiology Foundation and the American Heart Association, Inc
20.09.2016
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | BACKGROUND:Risk stratification in patients with type 3 long-QT syndrome (LQT3) by clinical and genetic characteristics and effectiveness of β-blocker therapy has not been studied previously in a large LQT3 population.
METHODS:The study population included 406 LQT3 patients with 51 sodium channel mutations; 391 patients were known to be event free during the first year of life and were the focus of our study. Clinical, electrocardiographic, and genetic parameters were acquired for patients from 7 participating LQT3 registries. Cox regression analysis was used to evaluate the independent contribution of clinical, genetic, and therapeutic factors to the first occurrence of time-dependent cardiac events (CEs) from age 1 to 41 years.
RESULTS:Of the 391 patients, 118 (41 males, 77 females) patients (30%) experienced at least 1 CE (syncope, aborted cardiac arrest, or long-QT syndrome–related sudden death), and 24 (20%) suffered from LQT3-related aborted cardiac arrest/sudden death. The risk of a first CE was directly related to the degree of QTc prolongation. Cox regression analysis revealed that time-dependent β-blocker therapy was associated with an 83% reduction in CEs in females (P=0.015) but not in males (who had many fewer events), with a significant sex × β-blocker interaction (P=0.04). Each 10-ms increase in QTc duration up to 500 ms was associated with a 19% increase in CEs. Prior syncope doubled the risk for life-threatening events (P<0.02).
CONCLUSIONS:Prolonged QTc and syncope predispose patients with LQT3 to life-threatening CEs. However, β-blocker therapy reduces this risk in females; efficacy in males could not be determined conclusively because of the low number of events. |
---|---|
AbstractList | Background:
Risk stratification in patients with type 3 long-QT syndrome (LQT3) by clinical and genetic characteristics and effectiveness of β-blocker therapy has not been studied previously in a large LQT3 population.
Methods:
The study population included 406 LQT3 patients with 51 sodium channel mutations; 391 patients were known to be event free during the first year of life and were the focus of our study. Clinical, electrocardiographic, and genetic parameters were acquired for patients from 7 participating LQT3 registries. Cox regression analysis was used to evaluate the independent contribution of clinical, genetic, and therapeutic factors to the first occurrence of time-dependent cardiac events (CEs) from age 1 to 41 years.
Results:
Of the 391 patients, 118 (41 males, 77 females) patients (30%) experienced at least 1 CE (syncope, aborted cardiac arrest, or long-QT syndrome–related sudden death), and 24 (20%) suffered from LQT3-related aborted cardiac arrest/sudden death. The risk of a first CE was directly related to the degree of QTc prolongation. Cox regression analysis revealed that time-dependent β-blocker therapy was associated with an 83% reduction in CEs in females (
P
=0.015) but not in males (who had many fewer events), with a significant sex × β-blocker interaction (
P
=0.04). Each 10-ms increase in QTc duration up to 500 ms was associated with a 19% increase in CEs. Prior syncope doubled the risk for life-threatening events (
P
<0.02).
Conclusions:
Prolonged QTc and syncope predispose patients with LQT3 to life-threatening CEs. However, β-blocker therapy reduces this risk in females; efficacy in males could not be determined conclusively because of the low number of events. BACKGROUND:Risk stratification in patients with type 3 long-QT syndrome (LQT3) by clinical and genetic characteristics and effectiveness of β-blocker therapy has not been studied previously in a large LQT3 population. METHODS:The study population included 406 LQT3 patients with 51 sodium channel mutations; 391 patients were known to be event free during the first year of life and were the focus of our study. Clinical, electrocardiographic, and genetic parameters were acquired for patients from 7 participating LQT3 registries. Cox regression analysis was used to evaluate the independent contribution of clinical, genetic, and therapeutic factors to the first occurrence of time-dependent cardiac events (CEs) from age 1 to 41 years. RESULTS:Of the 391 patients, 118 (41 males, 77 females) patients (30%) experienced at least 1 CE (syncope, aborted cardiac arrest, or long-QT syndrome–related sudden death), and 24 (20%) suffered from LQT3-related aborted cardiac arrest/sudden death. The risk of a first CE was directly related to the degree of QTc prolongation. Cox regression analysis revealed that time-dependent β-blocker therapy was associated with an 83% reduction in CEs in females (P=0.015) but not in males (who had many fewer events), with a significant sex × β-blocker interaction (P=0.04). Each 10-ms increase in QTc duration up to 500 ms was associated with a 19% increase in CEs. Prior syncope doubled the risk for life-threatening events (P<0.02). CONCLUSIONS:Prolonged QTc and syncope predispose patients with LQT3 to life-threatening CEs. However, β-blocker therapy reduces this risk in females; efficacy in males could not be determined conclusively because of the low number of events. BACKGROUNDRisk stratification in patients with type 3 long-QT syndrome (LQT3) by clinical and genetic characteristics and effectiveness of β-blocker therapy has not been studied previously in a large LQT3 population.METHODSThe study population included 406 LQT3 patients with 51 sodium channel mutations; 391 patients were known to be event free during the first year of life and were the focus of our study. Clinical, electrocardiographic, and genetic parameters were acquired for patients from 7 participating LQT3 registries. Cox regression analysis was used to evaluate the independent contribution of clinical, genetic, and therapeutic factors to the first occurrence of time-dependent cardiac events (CEs) from age 1 to 41 years.RESULTSOf the 391 patients, 118 (41 males, 77 females) patients (30%) experienced at least 1 CE (syncope, aborted cardiac arrest, or long-QT syndrome-related sudden death), and 24 (20%) suffered from LQT3-related aborted cardiac arrest/sudden death. The risk of a first CE was directly related to the degree of QTc prolongation. Cox regression analysis revealed that time-dependent β-blocker therapy was associated with an 83% reduction in CEs in females (P=0.015) but not in males (who had many fewer events), with a significant sex × β-blocker interaction (P=0.04). Each 10-ms increase in QTc duration up to 500 ms was associated with a 19% increase in CEs. Prior syncope doubled the risk for life-threatening events (P<0.02).CONCLUSIONSProlonged QTc and syncope predispose patients with LQT3 to life-threatening CEs. However, β-blocker therapy reduces this risk in females; efficacy in males could not be determined conclusively because of the low number of events. Risk stratification in patients with type 3 long-QT syndrome (LQT3) by clinical and genetic characteristics and effectiveness of β-blocker therapy has not been studied previously in a large LQT3 population. The study population included 406 LQT3 patients with 51 sodium channel mutations; 391 patients were known to be event free during the first year of life and were the focus of our study. Clinical, electrocardiographic, and genetic parameters were acquired for patients from 7 participating LQT3 registries. Cox regression analysis was used to evaluate the independent contribution of clinical, genetic, and therapeutic factors to the first occurrence of time-dependent cardiac events (CEs) from age 1 to 41 years. Of the 391 patients, 118 (41 males, 77 females) patients (30%) experienced at least 1 CE (syncope, aborted cardiac arrest, or long-QT syndrome-related sudden death), and 24 (20%) suffered from LQT3-related aborted cardiac arrest/sudden death. The risk of a first CE was directly related to the degree of QTc prolongation. Cox regression analysis revealed that time-dependent β-blocker therapy was associated with an 83% reduction in CEs in females (P=0.015) but not in males (who had many fewer events), with a significant sex × β-blocker interaction (P=0.04). Each 10-ms increase in QTc duration up to 500 ms was associated with a 19% increase in CEs. Prior syncope doubled the risk for life-threatening events (P<0.02). Prolonged QTc and syncope predispose patients with LQT3 to life-threatening CEs. However, β-blocker therapy reduces this risk in females; efficacy in males could not be determined conclusively because of the low number of events. |
Author | Tester, David J Benhorin, Jesaia Andrews, Mark L Shimizu, Wataru Zareba, Wojciech Qi, Ming Schwartz, Peter J Peterson, Derick R Kamakura, Shiro Crotti, Lia Kaufman, Elizabeth S Aiba, Takeshi Bezzina, Connie R Kanters, Jørgen K Miyamoto, Yoshihiro Alders, Marielle Lopes, Coeli Spazzolini, Carla Hofman, Nynke Wilde, Arthur A.M Polonsky, Bronislava Moss, Arthur J Ackerman, Michael J Goldenberg, Ilan McNitt, Scott Towbin, Jeffrey A Robinson, Jennifer L |
AuthorAffiliation | From AMC Heart Centre, Department of Clinical and Experimental Cardiology (A.A.M.W., C.R.B.) and Department of Clinical Genetics (N.H., M.A.), Academic Medical Center, Amsterdam, The Netherlands; Cardiology Division of the Department of Medicine (A.J.M., C.L., W.Z., I.G., J.L.R., M.L.A., S.M., B.P.), the Department of Biostatistics (D.R.P.), and the Department of Pathology (M.Q.), University of Rochester School of Medicine and Dentistry, Rochester, NY; Heart and Vascular Research Center, MetroHealth Campus of Case Western Reserve University, Cleveland, OH (E.S.K.); Department of Cardiovascular Medicine, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan (W.S.); Department of Cardiology Bikur Cholim Hospital, Jerusalem, Israel (J.B.); Department of Pediatrics, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH (J.A.T.); IRCCS Istituto Auxologico Italiano, Center for Cardiac Arrhythmias of Genetic Origin and Laboratory of Cardiovascular Genetics, Milan, Italy (C. |
AuthorAffiliation_xml | – name: From AMC Heart Centre, Department of Clinical and Experimental Cardiology (A.A.M.W., C.R.B.) and Department of Clinical Genetics (N.H., M.A.), Academic Medical Center, Amsterdam, The Netherlands; Cardiology Division of the Department of Medicine (A.J.M., C.L., W.Z., I.G., J.L.R., M.L.A., S.M., B.P.), the Department of Biostatistics (D.R.P.), and the Department of Pathology (M.Q.), University of Rochester School of Medicine and Dentistry, Rochester, NY; Heart and Vascular Research Center, MetroHealth Campus of Case Western Reserve University, Cleveland, OH (E.S.K.); Department of Cardiovascular Medicine, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan (W.S.); Department of Cardiology Bikur Cholim Hospital, Jerusalem, Israel (J.B.); Department of Pediatrics, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH (J.A.T.); IRCCS Istituto Auxologico Italiano, Center for Cardiac Arrhythmias of Genetic Origin and Laboratory of Cardiovascular Genetics, Milan, Italy (C.P. L.C., P.J.S.); Department of Cardiology, Gentofte University Hospital, Copenhagen, Denmark (J.K.K.); Departments of Medicine, Pediatrics, and Molecular Pharmacology & Experimental Therapeutics, Windland Smith Rice Sudden Death Genomics Laboratory, Mayo Clinic, Rochester, MN (D.J.T., M.J.A.); Division of Arrhythmia and Electrophysiology, Department of Cardiovascular Medicine (W.S.) and Department of Preventive Cardiology (Y.M.), National Cerebral and Cardiovascular Center, Suita, Japan; Department of Molecular Medicine, University of Pavia, Italy (L.C.); Princess Al-Jawhara Al-Brahim Centre of Excellence in Research of Hereditary Disorders, Jeddah, Kingdom of Saudi Arabia (A.A.M.W.); and Department of Cardiovascular, Neural and Metabolic Sciences, San Luca Hospital IRCCS Istituto Auxologico Italiano, Milan, Italy (L.C., P.J.S.) – name: 5 Department of Pathology, University of Rochester School of Medicine and Dentistry, Rochester, NY – name: 9 Department of Pediatrics, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH – name: 16 Princess Al-Jawhara Al-Brahim Centre of Excellence in Research of Hereditary Disorders, Jeddah, Kingdom of Saudi Arabia – name: 17 Chair of Sudden Death, Department of Family and Community Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia – name: 10 IRCCS Istituto Auxologico Italiano, Center for Cardiac Arrhythmias of Genetic Origin and Laboratory of Cardiovascular Genetics, Milan, Italy – name: 2 AMC Heart Centre, Department of Clinical Genetics, Academic Medical Center, Amsterdam, The Netherlands – name: 3 Cardiology Division of the Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY – name: 8 Department of Cardiology Bikur Cholim Hospital, Jerusalem, Israel – name: 4 Department of Biostatistics, University of Rochester School of Medicine and Dentistry, Rochester, NY – name: 11 Department of Cardiology, Gentofte University Hospital, Copenhagen, Denmark – name: 7 Department of Cardiovascular Medicine, Graduate School of Medicine, Nippon Medical School – name: 1 AMC Heart Centre, Department of Clinical and Experimental Cardiology, Academic Medical Center, Amsterdam, The Netherlands – name: 15 Institute of Human Genetics, Helmholtz Zentrum Muenchen, Neuherberg, Germany – name: 12 Departments of Medicine, Pediatrics, and Molecular Pharmacology & Experimental Therapeutics, Windland Smith Rice Sudden Death Genomics Laboratory, Mayo Clinic, Rochester, MN – name: 6 Heart and Vascular Research Center, MetroHealth Campus of Case Western Reserve University, Cleveland, OH – name: 13 Division of Arrhythmia and Electrophysiology, Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan – name: 14 Departments of Preventive Cardiology, National Cerebral and Cardiovascular Center, Suita, Japan |
Author_xml | – sequence: 1 givenname: Arthur surname: Wilde middlename: A.M fullname: Wilde, Arthur A.M organization: From AMC Heart Centre, Department of Clinical and Experimental Cardiology (A.A.M.W., C.R.B.) and Department of Clinical Genetics (N.H., M.A.), Academic Medical Center, Amsterdam, The Netherlands; Cardiology Division of the Department of Medicine (A.J.M., C.L., W.Z., I.G., J.L.R., M.L.A., S.M., B.P.), the Department of Biostatistics (D.R.P.), and the Department of Pathology (M.Q.), University of Rochester School of Medicine and Dentistry, Rochester, NY; Heart and Vascular Research Center, MetroHealth Campus of Case Western Reserve University, Cleveland, OH (E.S.K.); Department of Cardiovascular Medicine, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan (W.S.); Department of Cardiology Bikur Cholim Hospital, Jerusalem, Israel (J.B.); Department of Pediatrics, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH (J.A.T.); IRCCS Istituto Auxologico Italiano, Center for Cardiac Arrhythmias of Genetic Origin and Laboratory of Cardiovascular Genetics, Milan, Italy (C.P. L.C., P.J.S.); Department of Cardiology, Gentofte University Hospital, Copenhagen, Denmark (J.K.K.); Departments of Medicine, Pediatrics, and Molecular Pharmacology & Experimental Therapeutics, Windland Smith Rice Sudden Death Genomics Laboratory, Mayo Clinic, Rochester, MN (D.J.T., M.J.A.); Division of Arrhythmia and Electrophysiology, Department of Cardiovascular Medicine (W.S.) and Department of Preventive Cardiology (Y.M.), National Cerebral and Cardiovascular Center, Suita, Japan; Department of Molecular Medicine, University of Pavia, Italy (L.C.); Princess Al-Jawhara Al-Brahim Centre of Excellence in Research of Hereditary Disorders, Jeddah, Kingdom of Saudi Arabia (A.A.M.W.); and Department of Cardiovascular, Neural and Metabolic Sciences, San Luca Hospital IRCCS Istituto Auxologico Italiano, Milan, Italy (L.C., P.J.S.) – sequence: 2 givenname: Arthur surname: Moss middlename: J fullname: Moss, Arthur J – sequence: 3 givenname: Elizabeth surname: Kaufman middlename: S fullname: Kaufman, Elizabeth S – sequence: 4 givenname: Wataru surname: Shimizu fullname: Shimizu, Wataru – sequence: 5 givenname: Derick surname: Peterson middlename: R fullname: Peterson, Derick R – sequence: 6 givenname: Jesaia surname: Benhorin fullname: Benhorin, Jesaia – sequence: 7 givenname: Coeli surname: Lopes fullname: Lopes, Coeli – sequence: 8 givenname: Jeffrey surname: Towbin middlename: A fullname: Towbin, Jeffrey A – sequence: 9 givenname: Carla surname: Spazzolini fullname: Spazzolini, Carla – sequence: 10 givenname: Lia surname: Crotti fullname: Crotti, Lia – sequence: 11 givenname: Wojciech surname: Zareba fullname: Zareba, Wojciech – sequence: 12 givenname: Ilan surname: Goldenberg fullname: Goldenberg, Ilan – sequence: 13 givenname: Jørgen surname: Kanters middlename: K fullname: Kanters, Jørgen K – sequence: 14 givenname: Jennifer surname: Robinson middlename: L fullname: Robinson, Jennifer L – sequence: 15 givenname: Ming surname: Qi fullname: Qi, Ming – sequence: 16 givenname: Nynke surname: Hofman fullname: Hofman, Nynke – sequence: 17 givenname: David surname: Tester middlename: J fullname: Tester, David J – sequence: 18 givenname: Connie surname: Bezzina middlename: R fullname: Bezzina, Connie R – sequence: 19 givenname: Marielle surname: Alders fullname: Alders, Marielle – sequence: 20 givenname: Takeshi surname: Aiba fullname: Aiba, Takeshi – sequence: 21 givenname: Shiro surname: Kamakura fullname: Kamakura, Shiro – sequence: 22 givenname: Yoshihiro surname: Miyamoto fullname: Miyamoto, Yoshihiro – sequence: 23 givenname: Mark surname: Andrews middlename: L fullname: Andrews, Mark L – sequence: 24 givenname: Scott surname: McNitt fullname: McNitt, Scott – sequence: 25 givenname: Bronislava surname: Polonsky fullname: Polonsky, Bronislava – sequence: 26 givenname: Peter surname: Schwartz middlename: J fullname: Schwartz, Peter J – sequence: 27 givenname: Michael surname: Ackerman middlename: J fullname: Ackerman, Michael J |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27566755$$D View this record in MEDLINE/PubMed |
BookMark | eNqNUV1P2zAUtRAIWuAvIO9tLwF_xHE8aZOiiNFKHRVQni3Xcdpsrl3sBNR_v0QFtL7t6eqee865V_eMwbHzzgDwBaNrjDN8U04fy-dZsZjO74tJMWDXiOCc0CMwwoykScqoOAYjhJBIOCXkDIxj_N23GeXsFJwRzrKMMzYC89I2rtHKwiJujW4j9DVc7LYGUjjzbpU8LODTzlXBb8w3WDg4da0JTrWNd73oV2fbRpsBg09tV-0uwEmtbDSX7_UcPP-8XZSTZDa_m5bFLNGUI5pwhXKOU8ZTjjSvFatyrQVFosqytKZLQTBLM5yxfGnyXKOUYi6YrkiVErqsKD0HP_a-2265MdVwQlBWbkOzUWEnvWrk4cQ1a7nyr5IhijDnvcHXd4PgXzoTW7lpojbWKmd8F2X_ToIxEwL1VLGn6uBjDKb-XIORHAKRh4EMmNwH0muv_r3zU_mRQE_4vie8edt_Mf6x3ZsJcm2Ubdf_seAvmUec1A |
Cites_doi | 10.1001/jama.296.10.1249 10.1161/CIRCRESAHA.110.238469 10.1161/01.RES.0000069689.09869.A8 10.1046/j.1540-8167.2001.00630.x 10.1016/j.hrthm.2008.10.017 10.1111/j.1542-474X.2005.00077.x 10.1161/01.RES.85.12.1206 10.1046/j.1540-8167.2003.02545.x 10.1016/j.hrthm.2010.08.023 10.1172/JCI34057 10.1161/CIRCULATIONAHA.108.772533 10.1016/j.jacc.2009.08.028 10.1016/j.jacc.2006.08.057 10.1161/01.CIR.103.1.89 10.1111/j.1540-8167.2008.01246.x 10.1016/j.hrthm.2009.03.024 10.1016/j.hrthm.2011.05.020 10.1016/j.jacc.2009.05.029 10.1001/jama.292.11.1341 10.1161/01.CIR.0000125523.14403.1E 10.1161/CIRCULATIONAHA.110.950147 10.1161/01.CIR.101.14.1698 10.1016/j.hrthm.2014.11.009 10.1161/01.CIR.92.12.3381 10.1016/S0002-9149(01)02097-5 10.1056/NEJM197110142851607 10.1111/j.1542-474X.2001.tb00100.x 10.1056/NEJM199810013391404 10.1007/s00246-002-0169-5 10.1016/S0735-1097(99)00582-3 10.1016/S0735-1097(03)00554-0 10.1111/j.2517-6161.1972.tb00899.x 10.1161/CIRCULATIONAHA.106.665406 10.1016/S0008-6363(02)00445-5 |
ContentType | Journal Article |
Copyright | 2016 by the American College of Cardiology Foundation and the American Heart Association, Inc. 2016 American Heart Association, Inc. |
Copyright_xml | – notice: 2016 by the American College of Cardiology Foundation and the American Heart Association, Inc. – notice: 2016 American Heart Association, Inc. |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 5PM |
DOI | 10.1161/CIRCULATIONAHA.116.021823 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | CrossRef MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Anatomy & Physiology |
EISSN | 1524-4539 |
EndPage | 882 |
ExternalDocumentID | 10_1161_CIRCULATIONAHA_116_021823 27566755 10.1161/CIRCULATIONAHA.116.021823 |
Genre | Multicenter Study Journal Article |
GrantInformation_xml | – fundername: NHLBI NIH HHS grantid: R01 HL051618 – fundername: NHLBI NIH HHS grantid: R01 HL123483 – fundername: NHLBI NIH HHS grantid: R01 HL068880 – fundername: NHLBI NIH HHS grantid: R01 HL033843 |
GroupedDBID | - .XZ .Z2 01R 0R 1AW 1J1 29B 2WC 40H 4Q1 4Q2 4Q3 53G 5GY 5RE 5VS 71W 77Y 7O 7O~ 8RP AAAXR AAMOA AAMTA AAPBV AARTV AAWTL AAXQO ABBUW ABFLS ABOCM ABPMR ABPTK ABUFD ABXVJ ABZAD ACDDN ACEWG ACGFS ACRKK ACWDW ACWRI ACXNZ ADBBV ADCYY AE3 AENEX AFCHL AFUWQ AHMBA AHULI AHVBC AIJEX AJIOK ALMA_UNASSIGNED_HOLDINGS AMJPA ASCII ASPBG AVWKF AWKKM AZFZN BAWUL BOYCO BQLVK BYPQX C45 CS3 DIK DU5 E3Z EBS EJD EX3 F2K F2L F2M F2N F5P GX1 H0 H0~ H1 H13 HZ IKYAY IN IN~ JF9 JG8 JK3 K8S KD2 KMI KQ8 L-C L7B N9A N~7 N~B O0- O9- OAG OAH OBH OCB ODA OGEVE OHASI OK1 OL1 OLG OLH OLU OLV OLW OLY OLZ OPUJH OVD OVDNE OVIDH OVLEI OVOZU OWW OWY OXXIT P2P PQEST PQQKQ RAH RHF RIG RLZ RSW S4R S4S UPT V2I W2D WH7 WOQ WOW X3V X3W XZ YZZ Z2 ZA5 ZY1 ~H1 --- .-D .3C 0R~ 0ZK 18M 2FS 354 6PF AAAAV AAGIX AAHPQ AAIQE AAJCS AAQKA AASCR AASOK AASXQ AAUEB ABASU ABDIG ABJNI ABQRW ABVCZ ACCJW ACGFO ACILI ACLDA ACOAL ACXJB ADGGA ADHPY AE6 AEBDS AEETU AFDTB AFEXH AFSOK AGINI AHOMT AHQNM AHRYX AINUH AJNWD AJZMW AKULP ALMTX AMKUR AMNEI AOHHW AYCSE CGR CUY CVF DIWNM ECM EEVPB EIF ERAAH FCALG GNXGY GQDEL HLJTE HZ~ IKREB IPNFZ K-A K-F NPM ODMTH OHH OHYEH OJAPA OLB OWBYB OWU OWV OWX OWZ T8P TEORI TR2 TSPGW VVN W3M W8F XXN XYM YFH YOC YSK YYM ZFV ZZMQN AAYXX CITATION 7X8 5PM |
ID | FETCH-LOGICAL-c3703-7a0871457470c7fa5d8cc9309d664f3b9215461658be88c0431795cd2d423bd33 |
ISSN | 0009-7322 |
IngestDate | Tue Sep 17 21:32:00 EDT 2024 Sat Aug 17 03:50:33 EDT 2024 Fri Aug 23 02:57:33 EDT 2024 Wed Oct 16 00:01:43 EDT 2024 Thu Aug 13 19:50:11 EDT 2020 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 12 |
Keywords | death, sudden, cardiac risk assessment SCN5A protein, human arrhythmia, cardiac genetic testing long-QT syndrome |
Language | English |
License | 2016 American Heart Association, Inc. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c3703-7a0871457470c7fa5d8cc9309d664f3b9215461658be88c0431795cd2d423bd33 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Contributed equally to original concept and to authorship of this investigation |
PMID | 27566755 |
PQID | 1822115990 |
PQPubID | 23479 |
PageCount | 11 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_5030177 proquest_miscellaneous_1822115990 crossref_primary_10_1161_CIRCULATIONAHA_116_021823 pubmed_primary_27566755 wolterskluwer_health_10_1161_CIRCULATIONAHA_116_021823 |
ProviderPackageCode | OVOZU L-C C45 7O~ AARTV ABPMR OLH ASCII BYPQX OLG AAMOA ODA ABZAD ABBUW JK3 H0~ 1J1 OLV OLU JG8 OLW OLZ OLY F2K F2M F2L F2N OHASI AHVBC KMI OGEVE K8S OVLEI AJIOK OPUJH V2I .XZ S4R S4S 4Q1 OAG 4Q2 OVDNE 4Q3 AMJPA OAH OVD 71W AHULI ACEWG .Z2 N~7 IKYAY OVIDH AWKKM 40H N~B OBH X3V X3W ACDDN ACWRI BOYCO AIJEX AAXQO ~H1 AAMTA AAAXR OWW OCB OWY 01R ACXNZ OL1 AFCHL ABXVJ IN~ KD2 OXXIT 77Y ACWDW JF9 |
PublicationCentury | 2000 |
PublicationDate | 2016-September-20 |
PublicationDateYYYYMMDD | 2016-09-20 |
PublicationDate_xml | – month: 09 year: 2016 text: 2016-September-20 day: 20 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Circulation (New York, N.Y.) |
PublicationTitleAlternate | Circulation |
PublicationYear | 2016 |
Publisher | by the American College of Cardiology Foundation and the American Heart Association, Inc |
Publisher_xml | – name: by the American College of Cardiology Foundation and the American Heart Association, Inc |
References | 17470695 - Circulation. 2007 May 15;115(19):2481-9 12676817 - Circ Res. 2003 May 16;92(9):976-83 12741701 - J Cardiovasc Electrophysiol. 2003 Apr;14(4):337-41 15367556 - JAMA. 2004 Sep 15;292(11):1341-4 16968849 - JAMA. 2006 Sep 13;296(10):1249-54 5112730 - N Engl J Med. 1971 Oct 14;285(16):903-4 11333173 - Ann Noninvasive Electrocardiol. 2001 Apr;6(2):153-8 19467503 - Heart Rhythm. 2009 Jun;6(6):752-9 19926013 - J Am Coll Cardiol. 2009 Nov 24;54(22):2052-62 15051644 - Circulation. 2004 Apr 20;109(15):1826-33 12574983 - Pediatr Cardiol. 2003 Jan-Feb;24(1):70-2 18451998 - J Clin Invest. 2008 Jun;118(6):2219-29 17239714 - J Am Coll Cardiol. 2007 Jan 23;49(3):329-37 11728364 - Am J Cardiol. 2001 Dec 1;88(11):1311-4 21454796 - Circ Res. 2011 Apr 1;108(7):884-97 12123767 - Cardiovasc Res. 2002 Aug 1;55(2):279-89 18662191 - J Cardiovasc Electrophysiol. 2008 Dec;19(12):1289-93 19121811 - Heart Rhythm. 2009 Jan;6(1):113-20 10716483 - J Am Coll Cardiol. 2000 Mar 1;35(3):778-86 11136691 - Circulation. 2001 Jan 2;103(1):89-95 10590249 - Circ Res. 1999 Dec 3-17;85(12):1206-13 8521555 - Circulation. 1995 Dec 15;92(12):3381-6 12849668 - J Am Coll Cardiol. 2003 Jul 2;42(1):103-9 9753711 - N Engl J Med. 1998 Oct 1 ;339(14 ):960-5 16274417 - Ann Noninvasive Electrocardiol. 2005 Oct;10(4 Suppl):59-66 20816872 - Heart Rhythm. 2010 Nov;7(11):1616-22 11405394 - J Cardiovasc Electrophysiol. 2001 Jun;12(6):630-6 3623890 - Isr J Med Sci. 1987 Apr;23(4):302-4 25460862 - Heart Rhythm. 2015 Feb;12(2):440-8 21787999 - Heart Rhythm. 2011 Aug;8(8):1308-39 19118258 - Circulation. 2009 Jan 20;119(2):215-21 10758053 - Circulation. 2000 Apr 11;101(14):1698-706 20837891 - Circulation. 2010 Sep 28;122(13):1272-82 19695463 - J Am Coll Cardiol. 2009 Aug 25;54(9):832-7 e_1_3_3_17_2 e_1_3_3_16_2 e_1_3_3_19_2 e_1_3_3_13_2 e_1_3_3_36_2 e_1_3_3_12_2 e_1_3_3_15_2 Cox DR (e_1_3_3_18_2) 1972; 34 e_1_3_3_34_2 e_1_3_3_14_2 e_1_3_3_35_2 e_1_3_3_32_2 e_1_3_3_33_2 e_1_3_3_11_2 e_1_3_3_30_2 e_1_3_3_10_2 e_1_3_3_31_2 e_1_3_3_6_2 e_1_3_3_5_2 e_1_3_3_8_2 e_1_3_3_7_2 e_1_3_3_28_2 e_1_3_3_9_2 e_1_3_3_27_2 e_1_3_3_29_2 e_1_3_3_23_2 e_1_3_3_26_2 e_1_3_3_25_2 e_1_3_3_2_2 e_1_3_3_20_2 Medina A (e_1_3_3_24_2) 1987; 23 e_1_3_3_4_2 e_1_3_3_22_2 e_1_3_3_3_2 e_1_3_3_21_2 |
References_xml | – ident: e_1_3_3_2_2 doi: 10.1001/jama.296.10.1249 – ident: e_1_3_3_15_2 doi: 10.1161/CIRCRESAHA.110.238469 – ident: e_1_3_3_23_2 doi: 10.1161/01.RES.0000069689.09869.A8 – ident: e_1_3_3_25_2 doi: 10.1046/j.1540-8167.2001.00630.x – ident: e_1_3_3_21_2 doi: 10.1016/j.hrthm.2008.10.017 – ident: e_1_3_3_33_2 doi: 10.1111/j.1542-474X.2005.00077.x – ident: e_1_3_3_17_2 doi: 10.1161/01.RES.85.12.1206 – ident: e_1_3_3_29_2 doi: 10.1046/j.1540-8167.2003.02545.x – ident: e_1_3_3_14_2 doi: 10.1016/j.hrthm.2010.08.023 – ident: e_1_3_3_36_2 doi: 10.1172/JCI34057 – ident: e_1_3_3_9_2 doi: 10.1161/CIRCULATIONAHA.108.772533 – ident: e_1_3_3_6_2 doi: 10.1016/j.jacc.2009.08.028 – ident: e_1_3_3_3_2 doi: 10.1016/j.jacc.2006.08.057 – ident: e_1_3_3_8_2 doi: 10.1161/01.CIR.103.1.89 – ident: e_1_3_3_34_2 doi: 10.1111/j.1540-8167.2008.01246.x – volume: 23 start-page: 302 year: 1987 ident: e_1_3_3_24_2 article-title: Cardiac standstill as a cause of death in long QT syndrome. publication-title: Isr J Med Sci contributor: fullname: Medina A – ident: e_1_3_3_28_2 doi: 10.1016/j.hrthm.2009.03.024 – ident: e_1_3_3_4_2 doi: 10.1016/j.hrthm.2011.05.020 – ident: e_1_3_3_20_2 doi: 10.1016/j.jacc.2009.05.029 – ident: e_1_3_3_7_2 doi: 10.1001/jama.292.11.1341 – ident: e_1_3_3_27_2 doi: 10.1161/01.CIR.0000125523.14403.1E – ident: e_1_3_3_13_2 doi: 10.1161/CIRCULATIONAHA.110.950147 – ident: e_1_3_3_31_2 doi: 10.1161/01.CIR.101.14.1698 – ident: e_1_3_3_35_2 doi: 10.1016/j.hrthm.2014.11.009 – ident: e_1_3_3_30_2 doi: 10.1161/01.CIR.92.12.3381 – ident: e_1_3_3_16_2 doi: 10.1016/S0002-9149(01)02097-5 – ident: e_1_3_3_26_2 doi: 10.1056/NEJM197110142851607 – ident: e_1_3_3_32_2 doi: 10.1111/j.1542-474X.2001.tb00100.x – ident: e_1_3_3_11_2 doi: 10.1056/NEJM199810013391404 – ident: e_1_3_3_22_2 doi: 10.1007/s00246-002-0169-5 – ident: e_1_3_3_12_2 doi: 10.1016/S0735-1097(99)00582-3 – ident: e_1_3_3_10_2 doi: 10.1016/S0735-1097(03)00554-0 – volume: 34 start-page: 187 year: 1972 ident: e_1_3_3_18_2 article-title: Regression models and life-tables. publication-title: J Stat Soc [B] doi: 10.1111/j.2517-6161.1972.tb00899.x contributor: fullname: Cox DR – ident: e_1_3_3_5_2 doi: 10.1161/CIRCULATIONAHA.106.665406 – ident: e_1_3_3_19_2 doi: 10.1016/S0008-6363(02)00445-5 |
SSID | ssj0006375 |
Score | 2.6032097 |
Snippet | BACKGROUND:Risk stratification in patients with type 3 long-QT syndrome (LQT3) by clinical and genetic characteristics and effectiveness of β-blocker therapy... Risk stratification in patients with type 3 long-QT syndrome (LQT3) by clinical and genetic characteristics and effectiveness of β-blocker therapy has not been... Background: Risk stratification in patients with type 3 long-QT syndrome (LQT3) by clinical and genetic characteristics and effectiveness of β-blocker therapy... BACKGROUNDRisk stratification in patients with type 3 long-QT syndrome (LQT3) by clinical and genetic characteristics and effectiveness of β-blocker therapy... |
SourceID | pubmedcentral proquest crossref pubmed wolterskluwer |
SourceType | Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 872 |
SubjectTerms | Adolescent Adrenergic beta-Antagonists - therapeutic use Adult Cardiac Conduction System Disease Child Child, Preschool Electrocardiography - methods Female Heart Arrest - drug therapy Heart Arrest - etiology Humans Infant Long QT Syndrome - diagnosis Long QT Syndrome - drug therapy Male Registries Risk Assessment Sex Characteristics Sodium Channels - genetics Syncope - complications Syncope - drug therapy Young Adult |
Title | Clinical Aspects of Type 3 Long-QT Syndrome: An International Multicenter Study |
URI | https://www.ncbi.nlm.nih.gov/pubmed/27566755 https://search.proquest.com/docview/1822115990 https://pubmed.ncbi.nlm.nih.gov/PMC5030177 |
Volume | 134 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9RAFB60QhFEtPUSb0xBfFlSNzO5THwLsWVr1xZtFvYt5OoupUlJE8T-es9ccmNXrL6EZbIMIefLuc13zkHoPYGPmaW5pbPITnQzT2M9NiNXzwwjIxEFq5ELguyZPVuYX5bWsqcEieqSOj5MbrfWlfyPVGEN5MqrZP9Bst2msAC_Qb5wBQnD9U4y9tuyRk8UTApWBg8sJ3QyL4sf-rdgcqE6EmxNAIrqW07PzCpBKBwd8frrKlGzvbaN7BmkEECzyOa9XlWvmgp0TU8NUEPZ1Z0uKX0aNbnKvXbEsj4Le7FaX61vG8H_i-qoaoa5CcPmRAoij1kypU-JqZuW7FfUKVyVvlTIIgP9yeQcn9YUy7lEm1re5lreP_nuL-ayZ_DM46uHoh897U1be5x_dh4eL-bzMDhaBvfRA-K4Fqd_fj457ay2TR1rFx2o7T_-cfOx_7IRlGxyax_9LDnv4eZSlD0MnJfgCXqsog7sSQg9RfeyYg_tewCE8uoX_oAFD1gcsOyh3a-KbrGPzluAYQUwXOaYAwxTrACGW4B9wl6BR_DCA3hhAa9naHF8FPgzXU3g0BMKpkB3oikE1KYFMec0cfLISlmSuHTqprZt5jR2wWE0bQO82DhjLOGNmuDVJilJwUuPU0qfo52iLLKXCDPGaMy93dh1zWlOWAy2kmTMjKwEHLVcQ6R9r-G1bLQSigDVNsKxMPhaKIWhoYNWAiGoRX7WFRVZ2dyEcJdAsAO-loZeSIl02_KJBxAnWxpyRrLq_sBbro_vFOuVaL1u8QyC42jIHkk1lEXLf3_gV3d44NfoYf8tvUE7ddVkb8HzreN3ArK_Af0uq4c |
link.rule.ids | 230,315,786,790,891,27955,27956 |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinical+Aspects+of+Type+3+Long-QT+Syndrome%3A+An+International+Multicenter+Study&rft.jtitle=Circulation+%28New+York%2C+N.Y.%29&rft.au=Wilde%2C+Arthur+A+M&rft.au=Moss%2C+Arthur+J&rft.au=Kaufman%2C+Elizabeth+S&rft.au=Shimizu%2C+Wataru&rft.date=2016-09-20&rft.eissn=1524-4539&rft.volume=134&rft.issue=12&rft.spage=872&rft.epage=882&rft_id=info:doi/10.1161%2FCIRCULATIONAHA.116.021823&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0009-7322&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0009-7322&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0009-7322&client=summon |